FiercePharma

Calliditas, with a fresh approval for Tarpeyo in hand, launches IgA kidney disease education campaign

Swedish biotech Calliditas is going all-in when it comes to firsts: After getting the first drug specifically approved for immunoglobulin A (IgA) nephropathy last year, it’s now running the first ...
Yahoo Finance

Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review

Calliditas Therapeutics' CALT shares were up almost 7% on Aug 18, as the FDA accepted the submission of a supplement new drug application (sNDA) seeking to convert accelerated approval of Tarpeyo ...
Business Insider

Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency

STOCKHOLM, May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company submitted a Marketing Authorisation ...
STAT

Japanese conglomerate to buy Calliditas Therapeutics, maker of a kidney disease drug

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said ...
Nasdaq

Calliditas announces acquisition of remaining Genkyotex minority shares

STOCKHOLM, Oct. 7, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company now controls 100% of the share capital of ...
Seeking Alpha

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced publication in The Lancet of the full data from the Phase 3 NefIgArd ...
Yahoo Finance

Asahi Kasei offers to buy Sweden’s Calliditas for $1.04bn

Japanese company Asahi Kasei has made a public cash offer for the acquisition of all shares in the Swedish drugmaker Calliditas for Skr11.16bn ($1.04bn). The deal would involve the purchase of ...
Seeking Alpha

Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital

STOCKHOLM, Dec. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a term loan of 92 ...
MarketWatch

Calliditas Therapeutics stock jumps as kidney treatment gets FDA approval

Calliditas Therapeutics AB’s American depositary receipts CALT jumped 15% premarket on Thursday after the company said late Wednesday that its kidney treatment Tarpeyo received full approval from the ...
Business Insider

Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA

STOCKHOLM, Aug. 13, 2020 /PRNewswire/ -- Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7% of Genkyotex for €20.3M in cash at ...
Nasdaq

Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy

STOCKHOLM, March 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced the submission of a New Drug Application (NDA) to the U.S.
MarketWatch

Calliditas Therapeutics’ stock surges after $1.1 billion takeover bid

Calliditas Therapeutics AB’s American depositary receipts CALT jumped more than 70% premarket on Tuesday after a nearly $1.1 billion takeover bid from Japanese conglomerate Asahi Kasei. The Asahi ...